Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antigen-specific agents in development

M Sznol1, J Holmlund

  • 1Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD 20852, USA.

Seminars in Oncology
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC).

International journal of radiation oncology, biology, physics·2021
Same author

Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Phase i/ii trial of 5-Fluorouracil, leucovorin, Zidovudine and dipyridamole for patients with metastatic colorectal-cancer, renal-cell carcinoma and malignant-melanoma.

International journal of oncology·2011
Same author

A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.

Oncogene·2010
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Targeting tumor antigens with vaccines or monoclonal antibodies (MoAbs) offers promising anticancer therapies. Current research focuses on optimizing immunization strategies and developing advanced antibody constructs for improved efficacy.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Tumor antigens present unique targets for cancer therapy.
  • Exploiting antigen differences between tumor and normal cells is a key strategy.
  • Antigen-specific agents, including vaccines and monoclonal antibodies (MoAbs), are under development.

Purpose of the Study:

  • To review the development of therapeutic anticancer agents targeting tumor antigens.
  • To highlight current research directions in anticancer vaccines and antibody-based therapies.

Main Methods:

  • Review of preclinical and clinical data on antigen-specific anticancer agents.
  • Analysis of ongoing research in vaccine immunization approaches.
  • Examination of advancements in monoclonal antibody (MoAb) construct development.

Related Experiment Videos

Main Results:

  • Numerous antigen-specific agents are in late preclinical or clinical development.
  • Anticancer vaccine research is focused on optimizing immunization methods.
  • Second- and third-generation MoAbs are being developed to enhance potency and tumor distribution while reducing immunogenicity.

Conclusions:

  • Targeting tumor antigens via vaccines and MoAbs represents a significant area of cancer therapeutic development.
  • Ongoing research aims to refine these immunotherapeutic strategies for greater clinical success.